AstraZeneca Pharma India quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	683	526	+29.7%
EBITDA	48.9	81.1	−39.7%
EBITDA margin	7.2%	15.4%	−8.2 pts
Profit before tax	50.8	74.7	−32.1%
Net profit	37.9	55.8	−32.1%
EPS	₹15.17	₹22.33	−32.1%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	683	579	612	559	526	480	440	408	388	383	306	311	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	9.2	6.0	5.1	6.2	11.2	16.2	8.0	8.2	8.3	8.7	9.7	8.4
	692	585	617	565	538	497	448	416	396	392	315	319
	0.0	0.0	0.0	0.0	9.5	94.3	69.9	77.1	45.9	33.6	37.5	38.8
	305	312	697	432	418	288	229	252	240	75.0	182	140
	143	81.9	−331	−108	−132	−123	−51.6	−103	−55.7	105	−70.8	−56.6
	79.2	45.7	93.8	60.5	64.5	66.1	62.4	68.0	61.0	58.0	63.2	65.3
	2.0	2.0	1.1	0.7	0.7	0.7	0.3	0.3	0.1	−0.1	0.6	0.5
	5.2	5.6	3.8	2.6	16.6	17.7	9.1	9.3	3.9	3.8	3.7	3.7
	107	77.8	107	99.0	85.3	68.4	53.9	61.5	58.0	62.3	79.2	70.9
	641	525	572	487	462	412	373	365	353	338	295	262
	48.9	60.9	44.8	75.2	81.1	86.4	77.0	52.5	38.1	49.4	15.1	52.8
	43.7	55.3	41.0	72.6	64.5	68.7	67.9	43.2	34.2	45.6	11.4	49.1
Profit
	51.0	59.2	45.1	78.1	75.1	84.2	75.6	51.0	42.4	54.4	20.4	57.0
	−0.2	−1.1	1.5	−5.3	−0.4	−5.7	−33.5	0.0	−57.6	0.0	0.0	16.4
	50.8	58.1	46.5	72.8	74.7	78.5	42.0	51.0	−15.2	54.4	20.4	73.4
	10.9	14.3	4.0	19.0	22.1	22.9	12.2	14.7	10.8	15.5	4.7	21.3
	2.0	−1.1	10.0	−0.4	−3.2	−2.7	−1.0	−2.1	−14.1	−0.6	−0.1	−0.3
	12.8	13.3	14.0	18.6	18.9	20.2	11.2	12.6	−3.4	14.9	4.6	21.0
	37.9	44.9	32.6	54.2	55.8	58.3	30.9	38.4	−11.8	39.5	15.8	52.4
	37.9	44.9	32.6	54.2	55.8	58.3	30.9	38.4	−11.8	39.5	15.8	52.4
	−0.3	−4.8	0.0	−0.3	0.6	1.5	−1.7	−1.7	0.7	0.2	0.1	0.3
	37.6	40.1	32.6	53.9	56.4	59.7	29.1	36.8	−11.0	39.7	15.9	52.7
Per share
	₹15.17	₹17.95	₹13.04	₹21.69	₹22.33	₹23.30	₹12.34	₹15.37	−₹4.72	₹15.79	₹6.32	₹20.95
	₹0.00	₹0.00	₹13.04	₹21.69	₹22.33	₹23.30	₹12.34	₹15.37	−₹4.72	₹15.79	₹6.32	₹20.95
Other comprehensive income — detail
	−0.3	−4.8	0.0	−0.3	0.6	1.5	—	—	—	—	—	—
	−0.4	−6.4	0.0	−0.4	0.8	2.0	−2.3	−2.2	0.7	0.3	0.1	0.4
	−0.1	−1.6	0.0	−0.1	0.2	0.5	—	—	—	—	—	—
	—	—	—	—	—	—	−0.6	−0.6	0.0	0.1	0.0	0.1
Per share — as-filed variants
	₹15.17	₹17.95	₹13.04	₹21.69	₹22.33	₹23.30	₹12.34	₹15.37	−₹4.72	₹15.79	₹6.32	₹20.95
	₹0.00	₹0.00	₹13.04	₹21.69	₹22.33	₹23.30	₹12.34	₹15.37	−₹4.72	₹15.79	₹6.32	₹20.95
Regulatory disclosures — filed alongside, not part of the P&L
	—	1,070	—	1,001	—	770	—	—	—	—	—	—
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	236	184	245	235	231	221	193	182	157	170	157	189
	34.5%	31.9%	40.1%	42.0%	43.9%	46.0%	43.9%	44.6%	40.5%	44.3%	51.5%	60.7%
Adjusted (ex-exceptional items) — derived
	51.0	59.2	45.1	78.1	75.1	84.2	75.6	51.0	42.4	54.4	20.4	57.0
	−0.2	−1.1	1.5	−5.3	−0.4	−5.7	−33.5	0.0	−57.6	0.0	0.0	16.4
	38.1	45.7	31.6	58.2	56.1	62.5	55.5	38.4	33.0	39.5	15.8	40.6
	₹15.24	₹18.28	₹12.63	₹23.27	₹22.44	₹24.99	₹22.19	₹15.37	₹13.21	₹15.79	₹6.32	₹16.26

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

ASTRAZEN₹6,237.00

AstraZeneca Pharma India Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersSANOFICONR PGHL SANOFI SENORES INNOVACAP MOREPENLAB IOLCP FDCMcap ₹15,593 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	311.1	305.8	383.2	387.5	408.0	440.3	480.5	526.3	559.1	611.6	578.6	682.8
Other Income	8.4	9.7	8.7	8.3	8.2	8.0	16.2	11.2	6.2	5.1	6.0	9.2
Total Income	319.4	315.4	391.9	395.9	416.2	448.3	496.6	537.6	565.3	616.7	584.6	692.0
Expenses
+ Cost of Materials Consumed	38.8	37.5	33.6	45.9	77.1	69.9	94.3	9.5	0.0	0.0	0.0	0.0
+ Purchases of Stock-in-Trade	139.9	181.5	75.0	240.3	251.9	228.8	287.9	417.6	432.4	697.1	312.3	304.6
+ Changes in Inventories	-56.6	-70.8	105.0	-55.7	-103.1	-51.6	-122.5	-131.7	-107.9	-330.7	81.9	142.6
+ Employee Benefit Expense	65.3	63.2	58.0	61.0	68.0	62.4	66.1	64.5	60.5	93.8	45.7	79.2
+ Finance Costs	0.5	0.6	-0.1	0.1	0.3	0.3	0.7	0.7	0.7	1.1	2.0	2.0
+ Depreciation & Amortisation	3.7	3.7	3.8	3.9	9.3	9.1	17.7	16.6	2.6	3.8	5.6	5.2
+ Other Expenses	70.9	79.2	62.3	58.0	61.5	53.9	68.4	85.3	99.0	106.6	77.8	107.5
Total Expenses	262.5	295.0	337.5	353.5	365.1	372.7	412.5	462.5	487.2	571.6	525.3	641.0
EBITDA	52.8	15.1	49.4	38.1	52.5	77.0	86.4	81.1	75.2	44.8	60.9	48.9
EBIT	49.1	11.4	45.6	34.2	43.2	67.9	68.7	64.5	72.6	41.0	55.3	43.7
Profit
PBT before Exceptional Items	57.0	20.4	54.4	42.4	51.0	75.6	84.2	75.1	78.1	45.1	59.2	51.0
+ Exceptional Items	16.4	0.0	0.0	-57.6	0.0	-33.5	-5.7	-0.4	-5.3	1.5	-1.1	-0.2
Pretax Income	73.4	20.4	54.4	-15.2	51.0	42.0	78.5	74.7	72.8	46.5	58.1	50.8
+ Current Tax	21.3	4.7	15.5	10.8	14.7	12.2	22.9	22.1	19.0	4.0	14.3	10.9
+ Deferred Tax	-0.3	-0.1	-0.6	-14.1	-2.1	-1.0	-2.7	-3.2	-0.4	10.0	-1.1	2.0
Tax Expense	21.0	4.6	14.9	-3.4	12.6	11.2	20.2	18.9	18.6	14.0	13.3	12.8
Net Income	52.4	15.8	39.5	-11.8	38.4	30.9	58.3	55.8	54.2	32.6	44.9	37.9
+ Net Income — Continuing Ops	52.4	15.8	39.5	-11.8	38.4	30.9	58.3	55.8	54.2	32.6	44.9	37.9
+ Other Comprehensive Income	0.3	0.1	0.2	0.7	-1.7	-1.7	1.5	0.6	-0.3	0.0	-4.8	-0.3
Total Comprehensive Income	52.7	15.9	39.7	-11.0	36.8	29.1	59.7	56.4	53.9	32.6	40.1	37.6
Per Share
Basic EPS	20.95	6.32	15.79	-4.72	15.37	12.34	23.30	22.33	21.69	13.04	17.95	15.17
Diluted EPS	20.95	6.32	15.79	-4.72	15.37	12.34	23.30	22.33	21.69	13.04	0.00	0.00
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	1.5	0.6	-0.3	0.0	-4.8	-0.3
+ Items NOT to be Reclassified to P&L	0.4	0.1	0.3	0.7	-2.2	-2.3	2.0	0.8	-0.4	0.0	-6.4	-0.4
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	0.5	0.2	-0.1	0.0	-1.6	-0.1
+ Tax on Items NOT to be Reclassified — alt tag	0.1	0.0	0.1	0.0	-0.6	-0.6	—	—	—	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	20.95	6.32	15.79	-4.72	15.37	12.34	23.30	22.33	21.69	13.04	17.95	15.17
Diluted EPS — Continuing Operations	20.95	6.32	15.79	-4.72	15.37	12.34	23.30	22.33	21.69	13.04	0.00	0.00
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period	—	—	—	—	—	—	770.1	—	1,001.3	—	1,070.4	—
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	188.9	157.5	169.6	157.1	182.1	193.2	220.9	230.9	234.6	245.2	184.4	235.6
Gross Margin %	60.74	51.51	44.27	40.54	44.62	43.89	45.97	43.87	41.96	40.09	31.86	34.50
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	57.0	20.4	54.4	42.4	51.0	75.6	84.2	75.1	78.1	45.1	59.2	51.0
− Exceptional Items (reconciliation)	16.4	0.0	0.0	-57.6	0.0	-33.5	-5.7	-0.4	-5.3	1.5	-1.1	-0.2
Net Income Adj (tax-effected)	40.6	15.8	39.5	33.0	38.4	55.5	62.5	56.1	58.2	31.6	45.7	38.1
EPS Adj	16.26	6.32	15.79	13.21	15.37	22.19	24.99	22.44	23.27	12.63	18.28	15.24
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

AstraZeneca Pharma India quarterly results

AstraZeneca Pharma India (NSE: ASTRAZEN) has not yet announced the date of its Q2 FY27 results (July–September 2026); they are due by 14 November 2026 under SEBI's 45-day rule. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹37.9 crore, down 32.1% from ₹55.8 crore in Q1 FY26 and down 15.5% from ₹44.9 crore in Q4 FY26. Revenue from operations was ₹683 crore, up 29.7% year on year and up 18.0% from the previous quarter.

Q2 FY26 results (a year earlier): 7 November 2025
Q1 FY27 results (the latest): 10 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results due by: 14 November 202645 days after the quarter (SEBI)
Q1 FY27 net profit: ₹37.9 Cr−32.1% vs Q1 FY26−15.5% vs Q4 FY26
Q1 FY27 revenue: ₹683 Cr+29.7% vs Q1 FY26+18.0% vs Q4 FY26
Q1 FY27 operating margin: 6.4%−5.9 pts vs Q1 FY26−3.2 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹54.2 CrRevenue ₹559 Cr
Q1 FY27 EPS (basic): ₹15.17

Questions

When will AstraZeneca Pharma India announce its Q2 FY27 results?

The date is not announced yet. Results for July–September 2026 are due by 14 November 2026 (45 days after the quarter, SEBI Regulation 33). Last year it reported Q2 FY26 on 7 November 2025.

What was AstraZeneca Pharma India's net profit in FY26?

Consolidated net profit was ₹188 crore in FY26 (April 2025–March 2026), up 62.0% from ₹116 crore in FY25. It was ₹162 crore in FY24 and ₹99.3 crore in FY23: up 88.9% over three years, 23.6% a year on average.

What was AstraZeneca Pharma India's revenue in FY26?

Revenue from operations was ₹2,276 crore in FY26 (April 2025–March 2026), up 32.6% from ₹1,716 crore in FY25. It was ₹1,296 crore in FY24 and ₹1,003 crore in FY23: up 126.9% over three years, 31.4% a year on average.

What will AstraZeneca Pharma India's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹54.2 crore and revenue from operations ₹559 crore. The latest quarter, Q1 FY27, had a net profit of ₹37.9 crore and revenue of ₹683 crore.

What were AstraZeneca Pharma India's Q1 FY27 results?

Consolidated net profit was ₹37.9 crore, down 32.1% from ₹55.8 crore in Q1 FY26 and down 15.5% from ₹44.9 crore in Q4 FY26. Revenue from operations was ₹683 crore, up 29.7% year on year and up 18.0% from the previous quarter.

How has AstraZeneca Pharma India's profit changed over the last four quarters?

Net profit by quarter: ₹54.2 crore in Q2 FY26, ₹32.6 crore in Q3 FY26, ₹44.9 crore in Q4 FY26 and ₹37.9 crore in Q1 FY27. That is ₹170 crore over the four quarters, down 7.5% from ₹183 crore in the four quarters before. Revenue from operations: ₹559 crore, ₹612 crore, ₹579 crore and ₹683 crore.

Where do these AstraZeneca Pharma India figures come from?

From AstraZeneca Pharma India's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.